Eli Lilly and Company (NYSE:LLY) Trading Up 4.3% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s share price traded up 4.3% during mid-day trading on Thursday . The stock traded as high as $1,140.46 and last traded at $1,125.0040. 3,765,402 shares changed hands during trading, an increase of 18% from the average session volume of 3,195,381 shares. The stock had previously closed at $1,078.78.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: WW International’s Weight Watchers Med+ is now integrated with LillyDirect, potentially expanding access to Eli Lilly’s GLP-1 obesity treatment ecosystem and reinforcing Lilly’s leadership in weight management. Weight Watchers Expands Reach Through LillyDirect Partnership (WW)
• Positive Sentiment: Multiple reports highlighted Eli Lilly as a strong investment idea, including IBD naming it Stock of the Day and other commentary pointing to buy signals, supportive of bullish momentum in the shares. Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals
• Positive Sentiment: Analyst-style coverage and market commentary emphasized Lilly’s broader pipeline, including gene editing, vaccines, and cancer drugs, suggesting the stock is being valued for more than just Zepbound and Mounjaro. Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
• Positive Sentiment: News around Lilly’s ATTAIN-MAINTAIN obesity trial and other clinical updates may have added confidence that the company still has multiple pipeline catalysts ahead. Lilly’s ATTAIN-MAINTAIN Trial: A Fresh Pill-Based Play in the Obesity Market
• Neutral Sentiment: Broader market headlines about tech weakness and Broadcom’s AI-chip guidance are unlikely to be a direct driver for Lilly, but they may be shaping overall market tone.
• Negative Sentiment: Lilly’s $1.9 billion kidney-disease partnership with Ascidian was described alongside a stock drop in one report, suggesting investors may be cautious about near-term spending or deal execution risk. Eli Lilly (LLY) Secures $1.9 Billion Partnership With Ascidian for Kidney Disease Therapies

Analyst Ratings Changes

Several research analysts have issued reports on the company. Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price objective for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Wolfe Research reiterated an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Finally, Berenberg Bank increased their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Stock Performance

The company has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 39.96, a price-to-earnings-growth ratio of 1.16 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a 50 day moving average price of $965.78 and a two-hundred day moving average price of $1,011.48.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the company posted $3.34 earnings per share. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts predict that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in LLY. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. increased its position in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares during the period. Flow Traders U.S. LLC acquired a new stake in Eli Lilly and Company in the second quarter worth about $356,000. Finally, Nebula Research & Development LLC acquired a new stake in Eli Lilly and Company in the second quarter worth about $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.